Birolo Leila, Sacchi Silvia, Smaldone Giovanni, Molla Gianluca, Leo Gabriella, Caldinelli Laura, Pirone Luciano, Eliometri Patrick, Di Gaetano Sonia, Orefice Ida, Pedone Emilia, Pucci Piero, Pollegioni Loredano
Dipartimento di Scienze Chimiche, Università degli Studi di Napoli Federico II, Napoli, Italy.
Dipartimento di Biotecnologie e Scienze della Vita, Università degli studi dell'Insubria, Varese, Italy.
FEBS J. 2016 Sep;283(18):3353-70. doi: 10.1111/febs.13809. Epub 2016 Aug 5.
The human flavoenzyme d-amino acid oxidase (hDAAO) degrades the NMDA-receptor modulator d-serine in the brain. Although hDAAO has been extensively characterized, little is known about its main modulator pLG72, a small protein encoded by the primate-specific gene G72 that has been associated with schizophrenia susceptibility. pLG72 interacts with neosynthesized hDAAO, promoting its inactivation and degradation. In this work, we used low-resolution techniques to characterize the surface topology of the hDAAO-pLG72 complex. By using limited proteolysis coupled to mass spectrometry, we could map the exposed regions in the two proteins after complex formation and highlighted an increased sensitivity to proteolysis of hDAAO in complex with pLG72. Cross-linking experiments by using bis(sulfosuccinimidyl)suberate identified the single covalent bond between T182 in hDAAO and K62 in pLG72. In order to validate the designed mode of interaction, three pLG72 variants incrementally truncated at the C terminus, in addition to a form lacking the 71 N-terminal residues, were produced. All variants were dimeric, folded, and interacted with hDAAO. The strongest decrease in affinity for hDAAO (as well as for the hydrophobic drug chlorpromazine) was apparent for the N-terminally deleted pLG72(72-153) form, which lacked K62. On the other hand, eliminating the disordered C-terminal tail yielded a more stable pLG72 protein, improved the binding to hDAAO, although giving lower enzyme inhibition. Elucidation of the mode of hDAAO-pLG72 interaction now makes it possible to design novel molecules that, by targeting the protein complex, can be therapeutically advantageous for diseases related to impairment in d-serine metabolism.
人类黄素酶 D-氨基酸氧化酶(hDAAO)可降解大脑中的 N-甲基-D-天冬氨酸受体调节剂 D-丝氨酸。尽管 hDAAO 已得到广泛表征,但对其主要调节剂 pLG72 却知之甚少,pLG72 是一种由灵长类特异性基因 G72 编码的小蛋白,该基因与精神分裂症易感性相关。pLG72 与新合成的 hDAAO 相互作用,促进其失活和降解。在这项研究中,我们使用低分辨率技术来表征 hDAAO-pLG72 复合物的表面拓扑结构。通过将有限蛋白酶解与质谱联用,我们能够绘制复合物形成后两种蛋白质中的暴露区域,并突出显示与 pLG72 形成复合物的 hDAAO 对蛋白酶解的敏感性增加。使用双(磺基琥珀酰亚胺)辛二酸酯进行的交联实验确定了 hDAAO 中的 T182 与 pLG72 中的 K62 之间的单一共价键。为了验证设计的相互作用模式,除了一种缺少 71 个 N 端残基的形式外,还制备了三种在 C 端逐渐截短的 pLG72 变体。所有变体均为二聚体,具有折叠结构,并与 hDAAO 相互作用。对于缺少 K62 的 N 端缺失的 pLG72(72-153)形式,对 hDAAO(以及对疏水性药物氯丙嗪)的亲和力下降最为明显。另一方面,去除无序的 C 端尾巴产生了一种更稳定的 pLG72 蛋白,改善了与 hDAAO 的结合,尽管酶抑制作用较低。阐明 hDAAO-pLG72 相互作用模式现在使得设计新型分子成为可能,这些分子通过靶向该蛋白质复合物,对于与 D-丝氨酸代谢受损相关的疾病可能具有治疗优势。